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The minimally invasive midvastus (MMV) surgical approach for total knee arthroplasty (TKA) 
is a less invasive technique that has been proposed to accelerate recovery over standard TKA, 
however, advantages are not yet definitively established. We investigated the cost-effectiveness 
of MMV TKA versus the standard medial parapatellar (MPP) approach for TKA alongside a 
randomized controlled trial in patients with knee osteoarthritis. Patients reported resource use as 
well as indirect costs, and health outcomes were measured using the EQ-5D-5L and the Western 
Ontario and McMaster Universities Osteoarthritis Index over the 12-month study period. The 
results of our net benefit regression analysis suggest MMV TKA may be cost-effective compared 
to MPP TKA from the payer perspective at willingness-to-pay (WTP) values between $1000 and 
$2000, and WTP values between $2000 and $20,000 from the societal perspective. 
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Summary for Lay Audience 
 
For patients with advanced knee osteoarthritis (OA), total knee replacement (TKR) is an 
established surgical procedure that has been shown to improve pain, function, and quality of life. 
Over the years, less invasive surgical approaches have been developed in efforts to improve 
short-term recovery, reduce complications, and shorten the length of stay in hospital following 
TKR. The midvastus approach is one such technique. The potential advantage of the midvastus 
approach over traditional approaches is that less soft tissue in the leg is cut during surgery, which 
may allow for faster recovery and thus reduce the length of stay in hospital. 
 
A shorter length of stay may reduce the hospital costs of TKR, although it is unknown whether 
the potential financial savings will be outweighed by possible complications related to early 
discharge from the hospital. 
 
Therefore, the aim of this study was to evaluate the clinical outcomes and costs of TKR using a 
midvastus surgical approach compared to the standard medial parapatellar approach in patients 
with knee OA. We randomly assigned consenting patients scheduled to have TKR to either 
surgical approach and followed them for 12-months.  
 
Patients completed questionnaires on their health care resource use (e.g., number of physician 
visits, tests, medications) and indirect costs (e.g, time off work/volunteering) related to their 
surgery. They also completed surveys on health outcome measures such as health-related quality 
of life, pain, and movement before surgery, two-weeks, six-weeks, three-months, and 12-months 
 
 iv 
after surgery. We calculated the average total costs and health benefits incurred by patients in 
each group over the 12-month study period. 
 
We found patients who had TKR with the midvastus approach experienced slightly greater 
health benefits than patients who had standard medial parapatellar TKR. Midvastus TKR patients 
also incurred fewer costs when considering societal costs which includes direct and indirect 
costs. Our findings highlight the importance of investigating patient-reported outcome measures 
and indirect costs. These results will help inform a future study evaluating the safety and cost-
effectiveness of outpatient TKR, where patients are discharged from the hospital on the same day 
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Osteoarthritis (OA) is a degenerative joint disease often causing localized pain and reduced 
mobility (Woolf & Pfleger, 2003). This condition can significantly impact the physical and 
psychosocial well-being of patients (Sharma & Felson, 1998), and presents a substantial financial 
burden to healthcare systems and society as a whole (Gupta et al., 2005; Marshall et al., 2015). 
Nearly 1 in 3 people over the age of 65 are affected by OA, and the prevalence is expected to rise 
as risk factors for developing OA become more common (Arthritis Alliance of Canada [AAC], 
2011; Hawker, 2019). Therefore, it is important to investigate the cost-effectiveness of 
treatments for OA to optimize health gains given the constraints on health care resources. 
 
For patients with advanced knee osteoarthritis, total knee arthroplasty (TKA) is an established 
surgical procedure that has been shown to improve pain, function, and health-related quality of 
life (Pollock et al., 2016; Bourne et al., 2010).  Over the years, less invasive surgical techniques, 
including the midvastus approach, have been developed in efforts to improve short-term 
recovery, reduce complications, and shorten the length of stay following TKA. The potential 
advantage of the midvastus approach is that a large portion of the insertion of the vastus medialis 
on the quadriceps tendon is preserved during surgery which may allow for accelerated recovery 
and thus a reduced length of stay in hospital following surgery (Haas et al., 2004; Berger et al, 





A shorter hospital stay is one means of reducing the overall costs of TKA. Although improved 
efficiency is important in healthcare delivery, we must also consider the safety, effectiveness, 
and patient satisfaction associated with new models of care. Further, it is unknown whether the 
potential financial savings of minimally invasive TKA will be outweighed by possible additional 
postoperative costs, such as increased readmissions and decreased quality of care.  
 
 Therefore, the objective of this study was to evaluate the cost-effectiveness of TKA using a 
minimally invasive midvastus (MMV) surgical approach compared to the standard medial 
parapatellar (MPP) approach in patients with knee OA based on a 12-month randomized 
controlled trial (RCT). Our findings will be used to inform the protocol of a future RCT 
















1.2 Literature Review  
1.2.1 Osteoarthritis  
Osteoarthritis is the most common type of arthritis (Murray et al., 1996), affecting nearly 1 in 3 
people over the age of 65 (AAC, 2011). This degenerative musculoskeletal disease affects all 
structures within a joint (Felson et al., 2006) and is characterized by loss of joint cartilage that 
leads to localized pain, reduced joint range of motion and mobility, and lower quality of life 
(Hunter et al., 2008). In Canada, OA is one of the leading causes of disability, as well as a major 
economic burden (Marshall et al., 2015). The number of people living with OA is projected to 
double by 2040 as populations age and life expectancy extends (AAC, 2011). The increasing 
prevalence of OA risk factors, including obesity, physical inactivity, and joint injury, are also 
likely contributing to the rising rates of OA (Hawker, 2019; Puig-Junoy & Ruiz Zamora, 2015). 
  
1.2.1.1 Disease burden in Canada  
Studies on the prevalence of osteoarthritis have shown that approximately 3.9 million Canadians 
are living with symptomatic OA (PHAC, 2020). Osteoarthritis is not only responsible for a very 
high number of primary health care visits and overall hospital costs, but there is also a significant 
socio-economic burden (Li et al., 2006). A survey by Gupta et al. (2005) estimated Canadian 
patients over the age of 55 with hip or knee arthritis incurred $2300 in direct costs and $12,900 
in indirect costs annually. These non-healthcare-related indirect costs took form in time lost from 
employment for patients and for unpaid informal caregivers, with caregiver time accounting for 
40% of indirect costs. Another study by Xie et al. (2007) estimated the annual direct costs per 
patient to be US$2878 and the indirect costs to be US$9847 in Canada. As the Canadian 




care system (Birtwhistle et al., 2015). The direct costs of OA in Canada were projected to 
increase from $2.9 billion to $7.6 billion from 2010 to 2030, with hospitalizations for joint 
replacement accounting for the highest costs (Sharif et al., 2015). 
  
1.2.1.2 Osteoarthritis of the Knee 
Almost any synovial joint can be affected by osteoarthritis, although weight-bearing joints such 
as the knees and hips are the most commonly impacted (PHAC, 2010). Knee OA specifically 
impacts over 10% of the older adult population (AAC, 2011; Zhang & Jordan, 2010) and 
accounts for 83% of OA disability (Vos et al., 2012).  
 
The lifetime risk of developing symptomatic OA in at least one knee is estimated to be 39.8% for 
men and 46.8% for women, with significantly higher odds seen in those who possessed risk 
factors including obesity and history of knee injury (Murphy et al., 2008). Other common risk 
factors for OA include age, sex, genetic predisposition, and mechanical factors, including 
malalignment and abnormal joint shape.  
 
The course of the disease can vary but is often progressive. Over time the hyaline articular 
cartilage, which covers and protects the ends of bones, breaks down, and bony remodeling 
occurs. This breakdown was once thought to be caused by the wear and tear associated with 
aging, however, osteoarthritis is now understood to be the result of disruption of the natural 
cartilage remodeling process (PHAC, 2010; Kraus et al., 2015). As articular cartilage is lost, the 
subchondral bone becomes exposed, leading to joint space narrowing and bone-on-bone 




(formation of osteophytes and subchondral bone sclerosis) and thickening of the capsule (Lories 
& Luyten, 2011; Loeser et al., 2012). Inflammation of the synovium as well as overproduction of 
matrix-degrading enzymes, leading to destabilization of the joint, and abnormal joint loading are 
also often seen with knee osteoarthritis (Blagojevic et al., 2010; Felson et al., 2000; Felson, 
2009; Troeberg & Nagase, 2012).  
 
Knee OA is commonly clinically characterized by joint pain that is gradual in onset and worse 
with activity, tenderness, limitation of movement, crepitus, and variable degrees of local 
inflammation (Hunter et al. 2008; Kraus et al., 2015).  
 
Progression of OA cannot be reversed, and no disease-modifying agents for the treatment of 
knee osteoarthritis currently exist, although interventions have been developed to reduce 
symptoms of knee OA and improve function (Woolf & Pfleger, 2003). Therapeutic exercise, 
weight management, and pain medications may help relieve symptoms (Dunlop et al., 2011; 
Bijlsma & Knahr, 2007; PHAC, 2010). In cases of severe osteoarthritis, when conservative 
management fails, surgical treatment, including knee arthroplasty, may be considered (Lützner et 
al., 2009). 
 
1.2.2 Total Knee Arthroplasty  
Total knee arthroplasty (TKA), also known as total knee replacement, is a surgical procedure to 
replace the arthritic parts of the bones at the knee joint (the tibia, femur, and sometimes the 
patella) with an orthopedic prosthesis. TKA is considered for patients with severe knee 




osteoarthritis was the primary diagnosis for 99.4% of primary total knee arthroplasty patients in 
Canada from 2019-2020 (CIHI, 2021). The surgery has been shown to be highly effective, 
resulting in significant improvements in pain, functioning, and health-related quality of life 
(Brandes et al., 2011; Shan et al., 2015), but is also very costly. The average inpatient cost is 
more than $9,000 per procedure and accounts for more than 594,000 acute care bed days in 
Canada annually (CIHI, 2018). Total knee replacements are among the top 3 inpatient surgeries 
performed in Canada, and in the last five years, the number of TKAs performed has increased by 
17.1% (CIHI, 2021). Given the frequency at which the procedure is performed, it is the focus of 
continuous analysis and improvement (King et al., 2011; Lan et al., 2020). 
 
1.2.2.1 The Medial Parapatellar and Midvastus Surgical Approaches  
Two commonly used surgical approaches that have been shown to be safe for TKA are the 
medial parapatellar and the midvastus approach.  
 
The medial parapatellar approach is the most commonly used approach for total knee 
arthroplasty and is usually completed using an anterior incision approximately 18 cm long. With 
this approach, the quadriceps tendon is split in line with the fibers, leaving a cuff of tendon 
attached to the vastus medialis muscle, and the patella is everted (Laskin et al., 2004). This 
approach allows for excellent exposure of the joint and surgical visualization (Weinhardt et al., 
2004, Migliorini et al., 2020), however, the damage on the insertion of the vastus medialis on the 
quadriceps tendon can result in a weakened extensor mechanism and unsatisfactory functional 
outcomes (Boerger et al., 2005; Haas et al., 2004). Additionally, with this approach, the patellar 




patellar dislocation, and anterior knee pain (Brick & Scott, 1988; Berger et al., 1998; Roysam & 
Oakley, 2001). Overall, the standard medial parapatellar approach for TKA has had excellent 
surgical results but can result in demanding and lengthy recovery periods, which may contribute 
to patient dissatisfaction (Laskin et al., 2004; King at al., 2007; Anderson et al., 1996; Maloney, 
2002).  
 
Aiming to reduce recovery time and achieve better postoperative results, less invasive 
approaches for TKA were developed (Tria & Scuderi, 2015). The midvastus approach is one 
surgical technique that was developed to reduce the injury to the quadriceps tendon and 
minimize the disruption to patellar blood supply (Haas et al., 2004). With this approach, the 
vastus medialis muscle is divided in the direction of its fibers, as opposed to the traditional 
method of splitting the quadriceps tendon above the patella (Engh & Parks, 1998). It was 
suggested that this might allow for patients to experience less pain, and early restoration of range 
of motion (ROM) and extensor mechanism strength, compared to the medial parapatellar 
approach (Haas at al., 2006; Bonutti et al., 2004). This accelerated recovery was also proposed to 
allow for a shorter hospital stay, although these theoretical advantages are still being evaluated in 










Figure 1.1: The standard medial parapatellar and midvastus approaches for total knee 
arthroplasty. 
 
The definition of minimally invasive surgery (MIS) TKA is not yet standardized. Some authors 
have suggested MIS TKA generally involves a skin incision of less than 14 cm and incisions 
between 2-3 cm into the quadriceps muscle (Laskin et al., 2004; Tenholder et al., 2005; Tria & 
Scuderi, 2015). Others suggest MIS TKA includes a smaller incision, typically does not require 
eversion of the patella, and involves less quadriceps splitting (Leopold, 2009). The midvastus 
and medial parapatellar approaches can both be performed using either standard or minimally 
invasive techniques (Ongoo et al., 2020). However, the medial parapatellar approach is still the 
most commonly used standard approach for TKA, while the midvastus approach is often 
performed using minimally invasive techniques. In a meta-analysis comparing the midvastus and 




invasive techniques in the midvastus group, compared to standard medial parapatellar TKA. Xu 
et al. (2014) also conducted a meta-analysis including only studies that compared minimally 
invasive midvastus TKA with standard medial parapatellar TKA. In an earlier meta-analysis 
comparing midvastus TKA to standard medial parapatellar TKA by Alcelik et al. (2012), nine 
studies where minimally invasive techniques were used for midvastus TKA and nine studies 
where standard techniques was used for midvastus TKA were included. They found similar 
trends for all outcomes measured in a subgroup analysis comparing the minimally invasive 
approach to the standard approach for midvastus TKA.  
 
Overall, these meta-analyses found the results from the studies analyzing the differences between 
midvastus and medial parapatellar TKA are conflicting. All authors have reported differences in 
short-term outcomes but a reduction in significant clinical advantages over time (Alcelik et al., 
2012; Liu et al., 2014; Xu et al., 2014). The midvastus approach was associated with 
significantly improved knee range of motion and decreased anterior knee pain visual analog 
scale (VAS) scores at one to two weeks postoperative, however, there were no statistical 
differences in knee society score (KSS), VAS, or ROM beyond six weeks (Xu et al., 2014; Liu et 
al., 2014).  Additionally, the midvastus approach has been associated with significantly longer 
operative time when compared to the standard medial parapatellar approach. This is possibly due 
to the greater surgical steps and reduced operation field required for less invasive techniques (Liu 
et al., 2014). Some investigators have raised questions about the risk of component malalignment 
and the learning curve associated with performing new minimally invasive techniques (Dalury 





In terms of the time to perform straight leg raise, lateral retinacular release, blood loss, hospital 
stay, and postoperative complications (wound infection, deep vein thrombosis), no differences 
have been found between patients undergoing midvastus TKA compared to medial parapatellar 
TKA (Liu et al., 2014).  
 
Other less invasive TKA approaches include the quadriceps-sparing approach, and the subvastus 
approach (Tenholder et al., 2005). Each approach has its advantages, however, due to the 
difficulty of the operations, limited visualization, and longer learning curve, these approaches 
have not gained as much popularity (Haas et al., 2004; Liu et al., 2014; Lin et al., 2020). 
 
1.2.3 Outpatient Total Knee Arthroplasty  
Overall improvements in surgical and anesthetic techniques, as well as accelerated clinical care 
pathways, have led to a reduction in the rate of complications and shorter lengths of stay 
following TKA. These clinical pathways involve the application of multidisciplinary strategies 
by various healthcare professionals, including extensive preoperative patient education, early 
mobilization, meticulous monitoring, and early preventive intervention for common 
postoperative medical complications (Pollock et al., 2016; Berger et al., 2009). Some authors 
have reported that reducing the length of stay in the hospital following joint arthroplasty can 
reduce costs without compromising patient outcomes (Bozic & Beringer, 2007; Teeny et al., 
2005; Berger et al., 2009; Isaac et al., 2005). Today the average length of stay in the hospital 
following surgery is 3 days, although TKA is increasingly being performed as an outpatient 
surgery – where the patient is discharged from the hospital on the same day as their surgery 




outpatient knee replacements performed in Canada, however outpatient procedures still only 
represent 1.3% of all total knee arthroplasties performed (CIHI, 2021). Initially, there was 
concern that patients who underwent outpatient total joint arthroplasty (TJA) may experience 
complications related to early discharge and require additional services post-discharge, however, 
studies have found that outpatient THA and TKA can be safe and effective when performed in 
appropriately selected patients (Berger et al, 2009; Berger et al., 2005; Kolisek et al., 2009; 
Pollock et al., 2016; Cassard et al., 2018; Mariorenzi et al., 2020). A systematic review of the 
literature by Pollock et al. (2016) found no increase in readmission rates or perioperative 
complications, and a high level of satisfaction among patients who underwent outpatient 
procedures.  
 
No surgical approach is regarded as the standard for outpatient TKA, although most associate 
surgical approaches that minimize soft tissue damage with the ability to safely discharge patients 
home quicker (Berger et al., 2005; Berger et al., 2006). In an early study by Berger et al. (2005), 
a minimally invasive quadriceps-sparing approach was used to enable patients to go home the 
same day as their surgery. In a study by Kolisek et al. (2009), patients in both the inpatient and 
outpatient group received a TKA with medial parapatellar approach using a 10- to 13-cm 
incision, avoiding patella eversion. In this study, however, outpatients were defined as patients 
who were discharged within 23 hours of surgery rather than on the same day as surgery. 
 
1.2.4 Health Economics  
As healthcare costs rise and societal resources become more scarce, efficient allocation of 




climate require that decision-makers choose treatments that provide the best quality of care and 
optimize health benefits while minimizing costs. To better support these decisions, evidence-
based research providing information on economic efficiency and value for money is necessary 
(Health Council of Canada, 2009). 
 
Economic evaluation provides a method of comparing alternative courses of action in terms of 
costs and clinical consequences to help prioritize different healthcare strategies. These analyses 
help support investment in interventions that generate the greatest health value compared to a set 
of alternatives. With the growing burden of osteoarthritis as well as the high costs associated 
with total knee arthroplasty, it is important to investigate cost-effective strategies that optimize 
health gains given limited healthcare resources. 
 
1.2.4.1 Cost-effectiveness of Midvastus Total Knee Arthroplasty  
Several studies have evaluated the clinical effectiveness of midvastus TKA (Alcelik et al., 2012; 
Liu et al., 2014; Xu et al., 2014; Aslam et al., 2017; Lin et al., 2020), however, we found no 
studies that have investigated the economic implications of this approach. 
 
A few authors have studied the costs associated with other minimally invasive approaches for 
TKA, although none have prospectively investigated costs after hospital discharge.  
Coon et al. (2005) retrospectively reviewed the procedural charges of patients who received a 
minimally invasive TKA (with the MIS Mini-Incision™ or MIS Quadriceps-Sparing™ 
techniques), compared to standard TKA. They found the cost of MIS TKA to be on average 




despite requiring a more expensive implant for MIS TKA and prolonged tourniquet times use 
due to an early learning curve, although they do not specify the source of the cost reduction. 
Additionally, this study only presented patient charges and not actual hospital costs and did not 
take post-discharge medication, rehabilitation, or time off work costs into consideration.  
 
A study by King et al. (2011) also found MIS TKA to be associated with lower patient charges, 
although the magnitude of the difference was much smaller. They conducted a retrospective 
analysis on the inpatient charges of patients undergoing TKA with a minimally invasive 
quadriceps-sparing approach compared to the standard medial parapatellar approach and found 
MIS TKA patients to have slightly higher operating room costs but lower acute care costs 
resulting in a difference of US$1047 (7.2%) in the total inpatient charges. 
 
These studies provide some evidence that minimally invasive TKA may be cost-saving in the 
peri-operative period from the payer perspective, however, there were some limitations to these 
studies that warrant further investigation.  
 
These studies only considered the direct costs of the procedure or inpatient hospital charges; 
however, it is important to consider costs beyond hospital discharge. Potential financial savings 
in the hospital may be outweighed by additional postoperative costs, such as increased 
emergency room or physician visits, or decreased quality of care due to early discharge from the 
hospital. Given the proposed advantages of less invasive surgery such as earlier return to 
function, the costs associated with outpatient physical therapy and other rehabilitation costs, as 




productivity losses, as well as time off for caregivers. Previous studies on the indirect costs 
associated with musculoskeletal disorders have estimated these costs may be three to five times 
greater than direct medical costs incurred by patients (Gupta et al., 2005; Leardini et al., 2004). 
The burden on caregivers is high in the early post-operative period following TKA (Zadzilka et 
al., 2018). Caregivers often assist with performing household chores, transportation, taking 
medication, and personal care for the first 7 to 30 days following surgery (Manohar et al., 2014; 
Zadzilka et al., 2018). With enhanced recovery care pathways and early discharge, more 
assistance may be required from caregivers as postoperative rehabilitation and care activities 
shift from the inpatient setting to the home. Thus, the potential impact on caregivers should also 
be considered as more responsibility is placed on them earlier (van den Berg et al., 2004; Zomar, 
2020).  
 
Additionally, as some studies have found minimally invasive TKA to be associated with 
component malalignment and an increase in the need for revision surgery (Dalury & Dennis, 
2005; Barrack et al., 2009), analyzing direct medical costs over a longer time may influence 
results.  
 
Another limitation of these studies was that they were non-randomized and included early 
learning curve patients with prolonged tourniquet times. Increased operation times have been 
associated with minimally invasive techniques; however, studies have shown operating times 
reduce as surgeons gain familiarity with the technique (King et al., 2007; Migliorini et al., 2020).  
 




economic evaluations which are required to inform decisions on value for care and changes to 
healthcare policy. To our knowledge, no studies to date have conducted full cost-effectiveness 
analysis comparing both costs and outcomes of midvastus TKA compared to medial parapatellar 
TKA.  
 
A few authors have investigated the economic impact of outpatient total joint arthroplasty 
(Crawdord et al., 2015). Lovald et al. (2014) conducted a retrospective cost-analysis on the 
average medical costs of patients who had different lengths of stay following TKA and found 
those in the outpatient group incurred $8527 less in costs attributed to knee OA compared to the 
standard length of stay group over two years. They do not mention which surgical approach was 
used in the procedures, although they credit the move to outpatient procedures to the use of less 
invasive surgical techniques, regional as opposed to generalized anesthesia, and the 
implementation of enhanced recovery pathways.  
 
The costs associated with a minimally invasive technique for outpatient total hip arthroplasty 
were compared to standard inpatient total hip arthroplasty in a study by Bertin (2005). The billed 
charges of patients undergoing minimally invasive outpatient THA were found to be 
approximately $4000 less compared to inpatient charges. A later study by Aynardi et al. (2014) 
also found outpatient THA to have significantly fewer billed charges. In this study, both groups 
underwent THA with a direct anterior approach which is a minimally invasive technique.  
 
No full economic evaluations have yet been published on the cost-effectiveness of outpatient 




scientific consensus on the benefits of different surgical approaches for TKA, further 
investigation into these techniques is warranted. The purpose of this trial was to inform the 







2 Methods  
2.1 Study Design 
We conducted cost-effectiveness analyses comparing the medial parapatellar surgical approach 
to the midvastus surgical approach for TKA. In the trial, we randomized patients to either 
surgical approach, with or without the use of a tourniquet using a 2x2 factorial design. This 
randomization technique was used to allow us to explore surgical approach and tourniquet use 
efficiently and simultaneously by including all participants in both analyses (Lubsen & Pocock, 
1994; Montgomery et al., 2003). Tourniquet use was expected to act independently from costs 
related to surgical approach, and results on clinical impact will be reported elsewhere. Here we 
present the results of cost-effectiveness comparisons between the surgical approach groups.  
All patients underwent primary total knee arthroplasty at London Health Science’s Centre, 
University Hospital between August 2017 and February 2020, using a cemented Triathlon™ 
(Stryker Orthopaedics, Mahwah, NJ, U.S.A.) implant by two fellowship-trained arthroplasty 
surgeons. We followed patients from their preoperative visit to 12 months post-surgery and 
collected data on healthcare resource use and clinical outcome measures at standard of care 
visits. The study was approved by the University of Western Ontario’s Research Ethics Board 
for Health Sciences Research Involving Human Subjects and registered at clinicaltrials.gov 
(NCT03081663).  
 





We included patients scheduled to undergo primary total knee replacement with osteoarthritis, 
varus knee alignment, and an American Society of Anesthetists (ASA) score of three or less. 
Patients were also required to be able to read and understand English (as printed instructions 
were provided in English only), have home or cell phone access, and have an adult to accompany 
them home and care for them post-operatively.  
  
We excluded patients who were diagnosed with inflammatory arthritis, had a body mass index 
(BMI) greater than 40 or less than 18, were skeletally immature, had an active or suspected latent 
infection at or about the joint, had inadequate bone stock for support or fixation of the prosthesis, 
hardware precluding intramedullary instrumentation, prior osteotomies of the femur or tibia, had 
cognitive or neuromotor conditions, significant pain management issues, or had a family history 
of anesthesia-related complications (e.g. malignant hypothermia, pseudocholinesterase 
deficiency, airway difficulties, obstructive sleep apnea). Patients were also excluded if they lived 
more than 90 minutes from the hospital, were without access to caregivers, were unable to go 
directly to their home after surgery, or had significant psychological or social issues that would 
prevent them from managing at home safely.  
  
We included patients who met these criteria, were willing and able to comply with follow-up 
requirements and self-assessments, and provided informed consent. 
  
2.3 Randomization 
Patients were enrolled in the trial at their preadmission visit to the hospital and were randomly 




parapatellar TKA, with or without a tourniquet, via a web-based system. We used block 
randomization stratified by surgeon and patients previous experience with TKA (whether 
themselves or a family member/friend they cared for post-surgery). We kept patients and research 
staff blinded to group allocation until the final study visit. 
  
2.4 Intervention 
2.4.1 Operative Procedure 
Both surgical approaches are currently used in the surgeons’ normal practices and are completed 
using a straight anterior midline incision. Distally the approaches are the same, entering next to 
the patellar tendon to the tibia, avoiding the patella. With the midvastus surgical approach, 
proximally the incision extended obliquely from the superior-medial corner of the patella in line 
with the muscle fibers of the vastus medialis obliquus muscle belly, allowing the quadriceps 
tendon to remain intact. For the medial parapatellar approach, the quadriceps was split in line 
with the quadriceps tendon fibers, leaving a 5 mm cuff of tendon medially. An intramedullary 
femoral guide and extramedullary tibial guide were used for patients who were randomized to 
medial parapatellar TKA. The surgeons only used computer-assisted navigation for patients who 
received a TKA with the midvastus approach as implant malalignment has been a concern with 
this approach. All other aspects of the surgery were kept the same between the groups.  
  
2.4.2 Postoperative Care 
All participants had to pass physiotherapy discharge criteria and followed standard postoperative 




Patients returned to the orthopedic outpatient clinic for a follow-up visit with the surgeon at two 
weeks, six weeks, three months, and 12 months after surgery.  
 
2.5 Outcome Measures 
We collected outcome measures from patients at their preadmission appointment (no more than 
one month prior to surgery), on the day of discharge from hospital, and at two-weeks, six-weeks, 
three-months, and 12-months post-surgery. In addition to these time points, cost data were also 
collected at six and nine months. We used a secure web-based data management system 
(EmPower Health Research, Inc, www.empowerhealthresearch.ca) which allowed patients to 
complete questionnaires online. Patients also had the option of completing hard copies of the 
questionnaires at each follow-up.  
 
2.5.1 Clinical Effectiveness  
Information on clinical effectiveness was collected directly from study participants. Patients 
completed the self-reported questionnaires at or no earlier than one week before each study visit. 
 
2.5.1.1 EQ-5D-5L 
The EQ-5D-5L is a preference-based health-state measure used to collect quality of life data 
directly from patients (Fransen & Edmonds, 1999). Unique health states are described using a 5-
digit number formed according to responses in five dimensions; mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression, each with five response levels (no problems, 




(Herdman et al., 2011; Janssen et al., 2013). Using a value set, which reflects the health 
preferences of the general public, health utility values can be derived from the EQ-5D-5L health 
states (Xie et al., 2016). Health utilities are required to estimate QALYs and are anchored at 0 
(dead) and 1 (full health), although negative values are possible for health states worse than dead 
(Jenkins et al., 2013; Wolowacz et al., 2016).  
The EQ-5D-5L has been shown to exhibit acceptable test-retest reliability in each domain (range 
0.61-0.77) in OA patients undergoing TKA (Conner-Spady et al., 2015). When compared with 
the earlier EQ-5D-3L, the EQ-5D-5L has been found to have better responsiveness, stronger 
convergent construct validity, and stronger correlations with the Western Ontario McMaster 
Osteoarthritis Index, Oxford Knee Score, and Short Form-12 (Jin et al., 2019). Additionally, 
individual EQ-5D-5L dimension response levels collected through electronic versions of the tool 
have not been found to significantly differ when compared with paper versions (Mulhern et al., 
2015).  
2.5.1.2 Western Ontario McMaster Osteoarthritis Index 
The Western Ontario McMaster Osteoarthritis Index (WOMAC) is a disease-specific 
questionnaire used to measure health status across three domains in patients with OA of the hip 
or knee (Bellamy & Buchanan, 1986). The tool is self-administered and comprised of 24 
questions total across three domains: five items relating to pain, two to stiffness, and 17 to 
physical function. Each question is scored on a scale from 0 (none) to 4 (extreme). Domains can 
be assessed individually, or they can be combined to create a global score to evaluate function 
and health. WOMAC scores can be linearly transformed to a 0–100 scale, with lower scores 





WOMAC is one of the most commonly used patient-reported outcome measures in patients with 
knee osteoarthritis and has been found to be valid, reliable, and responsive for detecting 
important health changes after total knee arthroplasty (White & Master, 2016; Walker et al., 
2019). Overall, the WOMAC has high test-retest reliability for the physical function and pain 
subsections and has been found to be highly predictive for primary TKA treatment success at 12-
months (Faucher et al., 2004; Giesinger et al., 2014). An electronic version of the WOMAC has 




2.5.2 Costs   
2.5.2.1 Surgical Costs 
We collected data on health care resource use at the patient level. Patients’ medical charts were 
reviewed from the time of admission for TKA to discharge to retrieve time spent in the post-
anaesthetic care unit (PACU) and surgical inpatient ward following surgery. The cost per unit 
time spent in each department was obtained from our institution’s case costing data and applied 
to each case.  
 
The remaining average costs related to the TKA procedure, included the cost of food services, 
operating room, day surgery pre-and-post-operative care, clinical laboratory services, medical 
imaging, respiratory services, pharmacy costs, physiotherapy, and was obtained from hospital 
case costing data. Surgeon and anesthesiologist billing was also included in this total and valued 




Care [MOHLTC], 2020). The cost of the prosthetic implant was not included as prosthesis costs 
vary widely and can largely influence TKA cost. All patients in the study had cemented Stryker 
Triathlon implant.  
 
2.5.2.2 Healthcare Resource Use 
Patients kept daily diaries for the first 14 days postoperative and completed self-reported cost 
questionnaires at two weeks, six weeks, three-, six-, nine-, and 12-months post-surgery. Resource 
use and costs were collected across 14 domains including visits to their family physician, 
surgeon, and other healthcare professionals (e.g., physical therapists, occupational therapists, 
etc.), information about hospitalizations and emergency room visits, diagnostics (e.g., imaging, 
laboratory), medications, calls to the surgeon’s office, and any other related expenses. 
 
To estimate costs directly covered by the provincial publicly funded healthcare, we applied the 
unit prices from provincial databases. We obtained the unit prices of physician services, 
including family physician and specialists from the Ontario Ministry of Health Schedule of 
Benefits (MOHLTC, 2020). We valued walk-in clinic costs at the family physician fee and 
valued calls to physicians or specialists which lasted at least 10 minutes as a partial assessment. 
The cost of a physiotherapist visit was taken from the Ontario Quality-Based Procedures 
Bundled Pricing (Health Quality Ontario & MOHLTC, 2013) if patients reported their visits 
were covered by the provincial insurance. Medication costs were obtained from the Ontario Drug 





Self-reported costs were used if patients reported that they paid for other healthcare professional 
visits or medications out-of-pocket or through private insurance. 
 
2.5.2.3 Indirect Costs  
Patients also reported information about indirect productivity losses such as the amount of time-
off paid employment, homemaking, volunteer activities, and caregiving. We also requested 
patients report the number of hours of unpaid assistance received from friends or family, as well 
as the hours of paid assistance they received.  
 
We used the average Canadian wage for individuals 25 years and older reported by Statistics 
Canada in June 2021 to place a monetary figure on time off from paid employment, for both 
patients and their caregivers (Statistics Canada, 2021). The current value of minimum wage in 
Ontario was used to value participants time away from volunteer or homemaking activities and 
unpaid assistance received (Government of Ontario, 2021). We estimated the total cost for each 
patient over the 12-month follow-up period and reported all costs in 2021 Canadian dollars. 
Resource use for unrelated conditions was not included. 
 
2.6 Sample Size  
A formal sample size calculation was not conducted as the main goal of this pilot study was to 
inform the surgical protocol of a future randomized trial investigating outpatient total knee 
arthroplasty. Based on the participating surgeons’ caseload, we estimated 80 participants could 





2.7 Data Analysis  
We analyzed data using Stata v. 11.2 (StataCorp LP, College Station, TX, USA) and all 
statistical tests were two-tailed at a significance level of 0.05.  
 
All outcomes were tested for normality by looking at boxplots and assessing histograms for 
kurtosis and skewness. We used descriptive statistics to present the demographic and surgical 
characteristics for each group. We report means and standard deviation (SD) for all normally 
distributed continuous measures (age, height, operative time), and frequencies and proportions 
for categorical variables (sex, contralateral knee symptoms, ASA score). We reported the median 
and interquartile range for non-normally distributed continuous measures. 
 
We used non-parametric bootstrapping with 1000 replications to estimate totals if data were 
skewed and presented 95% confidence intervals (CI) with standard errors (SE) (Efron, 1979; 
Briggs et al. 1997; Tambour & Zethraeus, 1998; Hesterberg, 2011). We conducted the primary 
analysis following the intention to treat principle.   
 
2.7.1 Cost-effectiveness analyses  
Costs are often categorized as direct medical costs, direct non-medical costs, and indirect costs. 
Direct medical costs refer to the costs associated with the health services (e.g., treatment and 
follow-ups, medications) which are relevant to the treatment option being considered. Direct 
non-medical costs include patient out-of-pocket expenses associated with the intervention (e.g., 
travel, house modifications, and informal caregiving), while indirect costs include productivity 





We conducted cost-effectiveness analyses from both the healthcare payer (HCP) and societal 
(SOC) perspectives. In Canada, we have a single-payer system where the funding and 
reimbursement decisions are made by provincial governments (e.g., the Ontario Ministry of 
Health and Long-Term Care) on behalf of the population covered. The HCP perspective includes 
direct costs covered by the Ontario Ministry of Health Insurance Plan (e.g., visits to healthcare 
professionals, procedures, tests, hospitalizations, and visits to emergency rooms). For patients 
aged 65 years and older, we also included prescription medications covered by the Ontario Drug 
Benefit in the HCP perspective. 
 
The societal perspective included both direct and indirect costs (time-off paid employment, 
volunteer activities, homemaking, caregiving, and caregiver assistance), as well as out-of-pocket 
expenses to patients.  
 
Once aggregated, we calculated incremental cost-effectiveness ratios (ICER) by taking the ratio 
of the mean values of incremental cost by the incremental effect between the MPP and MMV 
groups (ICER = ΔC/ΔE, C = cost, and E = effectiveness).  
 
Cost-utility analyses were conducted using the difference in QALYs derived from EQ-5D-5L 
utility scores as the measure of effect. QALYs are a generic outcome metric which can reflect 
preference for different health effects and enables comparisons across health care interventions. 
QALYs were estimated by calculating the area under the curve, which can be thought of as the 




at that state (Drummond et al., 2015). We also conducted a cost-effectiveness analysis using 
WOMAC total score at 12-months as the measure of effect.  
 
2.7.2 Net Benefit Regression (NBR) 
We used a NBR framework to allow for consideration of incremental cost and effect of the 
intervention in addition to a willingness-to-pay (WTP) value (Hoch et al., 2002). A WTP value is 
the maximum acceptable amount one is willing-to-pay to achieve one additional unit 
improvement in effect.  
 
Incremental net benefit (INB) was calculated using the equation: INB = WTP* DE - DC 
A positive INB, or INB>0, indicates the midvastus approach is more cost-effective than the 
medial parapatellar approach. Separate NBR models were developed for the HCP and societal 
perspectives, and a range of willingness–to-pay values from $0 – $50,000 were considered. We 
included age, sex, BMI, baseline utility, and WOMAC score as covariates in our model.  
 
2.7.3 Uncertainty  
Cost-effectiveness acceptability curves (CEAC) were also used to characterize the uncertainty 
around the cost-effectiveness estimates (Hoch et al., 2006). The CEACs graphically present the 
probability that TKA performed with the midvastus approach is cost-effective compared to the 
medial para-patellar approach over a wide range of willingness to pay values per outcome 
gained. We constructed CEACs from the healthcare payer and societal perspectives considering 





2.7.4 Sensitivity Analysis  
We conducted one-way sensitivity analyses 1) analyzing participants who crossed over as treated 
and 2) removing outliers (residuals > 2 standard deviations) from both perspectives.  
  
2.7.5 Missing Data 
We used multivariate imputation using chained equations (MICE) methods to impute missing 
utility data and WOMAC scores. Estimates of total costs were also imputed for patients lost to 
follow-up at 12-months. We used predictive mean matching pulling from five nearest neighbors 
to generate 5 imputations which were pooled to create one final data set for analysis. To increase 
the accuracy of the imputed values, age, sex, BMI, previous TKA (yes or no), and smoking 
status (yes or no) were used as covariates.  
 
2.8 Source of Funding  








3.1 Patient Flow  
Eighty-six patients were randomized for this study, with 40 allocated to the standard medial 
parapatellar group (MPP), and 46 allocated to the minimally invasive midvastus (MMV) group 
(Figure 3.1). Following randomization, one participant was excluded as they no longer met the 
inclusion criteria (diagnosed with obstructive sleep apnea), and four patients requested to be 
withdrawn from the study. Two patients (MMV and MPP) withdrew at the baseline visit, one 
patient (MPP) withdrew at the two-week study visit, and one patient (MMV) requested to 
withdraw at the six-month visit. Nine participants crossed over, with two patients in the MPP 
group having TKA with a MMV approach, and seven patients in the MMV group having surgery 
with the standard MPP approach.  
 
Due to COVID-19 restrictions, some patients were missed at the six-month follow-up (26 
patients in the MPP group and 27 patients in the MMV group), and at the nine-month follow-up 
(15 patients in the MPP group and 24 patients in the MMV). We were able to contact the 
majority (95.4%) of patients missed at the 12-month follow-up and asked patients to report all 
relevant costs since their last study visit. Missing 12-month cost data values were imputed for 3 
patients in the MPP group (7.9%) and 2 patients in the MMV group (4.5%). 4.6% of missing 












3.2 Demographics and Clinical Characteristics   
 Demographic and clinical characteristics were similar between the two groups across most 
measures with the exception of height (p = 0.044), weight (p = 0.001), and BMI (p = 0.014) 
which was significantly higher in the MPP group (Table 3.1). The mean age in the MPP group 
was 67 years compared to 70 years in the MMV group, and there was a greater percentage of 
male participants, although not significantly different. Majority of patients were considered to 
have a severe systemic disease according to their ASA score and had symptoms of osteoarthritis 
in their contralateral knee. There was also a lower proportion of patients with Charlson 
Comorbidity Index scores of two or greater in the MPP group compared to the MMV group. 
Table 3.1. Baseline demographics and clinical characteristics. 
Characteristic  MPP TKA (n=38) 
Mean (SD) 
MMV TKA (n=45) 
Mean (SD) 
P value 
Height, cm  171.87 (10.51) 166.96 (11.18) 0.04 
Weight, kg 96.53 (18.72) 84 (15.58) >0.01 
BMI, kg/m2  32.47 (4.16) 30.07 (4.47) 0.01 
Age, y  66.82 (7.53) 69.76 (7.29) 0.08 
Sex (Male), n (%)  21 (55.26) 18 (40.00) 0.17 
Other Knee Symptoms, n (%)  26 (68.42) 29 (64.44) 0.70 
Previous TKA, n (%)  11 (28.95) 9 (20.00) 0.34 
Surgery on Dominant Knee, n (%) 17 (44.74) 16 (35.56) 0.39 
Smokers, n (%)  
  
0.61 
0 (never smoked) 14 (36.84) 23 (51.11) 
 
1 (quit >12 months) 20 (52.63) 19 (42.22) 
 
2 (quit <12 months) 1 (2.63) 1 (2.22) 
 
3 (yes) 3 (7.90) 2 (4.44) 
 
ASA Score, n (%) 
  
0.48 
1 1 (2.63) 0  
2 16 (42.11) 17 (37.78)  
3 21 (55.26) 28 (62.22)  
Charlson Comorbidity Index 
  
0.25 
0 24 (63.16) 29 (64.44) 
 
1 11 (28.95) 7 (15.56) 
 
2 3 (7.89) 8 (17.78) 
 





3.3 Surgical Characteristics   
Surgical time and time in the Post Anesthesia Care Unit (PACU) was similar between the groups 
(Table 3.2). The majority of patients received spinal anesthesia while three patients in the MPP 
group and one patient in the MMV group received general anesthesia. There were two patients in 
the MPP group who were unable to pass physiotherapy discharge criteria after surgery and had to 
remain in hospital while waiting for a transfer to a rehabilitation facility. These patients had 
lengths of stays greater than 140 hours. Additionally, one participant in the MPP group was 
discharged from the hospital on the same day as their surgery. As this outcome was not normally 
distributed, we reported medians and interquartile ranges. The median length of stay in the MPP 
group was 44.5 hours compared to 44.0 hours in the MMV group (p = 0.22).  
 
Table 3.2. Surgical characteristics.  
 
MPP TKA MMV TKA Mean Difference P value  
Mean (SD unless stated) (95% CI) 
Surgery Time, min  83.37 (14.45) 86.56 (17.72) 3.19 (-3.96, 10.34) 0.38 
Procedure Time, min  55.0 (8.79) 58.2 (8.88) 3.2 (-0 .67, 7.07) 0.10 
Tourniquet Time, min  
    
   Standard Tourniquet  53.48 (8.72) 58.52 (8.72) 5.04 (-0.16, 10.25) 0.06 
   Minimal Tourniquet 8.24 (2.34) 13.35 (3.07) 5.12 (-2.95, 13.18) 0.21 
Anaesthesia, n (%)  
    
   Spinal  35 (92.11) 44 (97.78) 
 
0.41 
   General  3 (7.90) 1 (2.22) 
  
Length of Stay, hrs, 
median, (IQR) 
44.50 (26.0, 50.0) 44.00 (26.0, 48.0) 
 
0.22 
Admission to PACU, 
hrs  
3.63 (0.91) 3.80 (0.70) 0.16 (.52, 0.19) 0.36 
Time in PACU, hrs  2.65 (1.40) 2.70 (2.94) 0.05 (-1.00, 1.10) 0.94 
Ward to Discharge, 
hrs, median, (IQR) 
42.0 (23.0, 47.0) 40.0 (22.0, 45.0) 
 
0.16 
SD = standard deviation, CI = confidence interval, IQR = interquartile range, PACU = post 






3.4 Outcome Measures  
3.4.1 Effectiveness Outcomes  
Utility values were significantly higher in the MMV group compared to the MPP group at three-
months postoperative, although there was no significant difference at 12-months (Table 3.3). 
WOMAC total scores were statistically significantly higher in the MMV group at both the three-
month and 12-month visits. Both utility value and WOMAC total score were slightly higher in 
the MMV group at baseline, although the difference was not significant. Patients in both groups 
demonstrated improvements in total WOMAC score from baseline to 12-months however the 
difference in improvement did not the reach the minimally clinically important difference 
(MCID) of least 10 points (Clement, 2018).  
 
Table 3.3. EQ-5D Utility Scores and WOMAC total scores measured from baseline to 12-months 
postoperative. 
 MPP TKA MMV TKA Mean Difference P value 
 Mean (SD) Mean (SD) (95% CI)  
EQ5D Utility Values     
Pre-operative 0.664 (0.028) 0.678 (0.034) 0.014 (-0.053, 0.080) 0.69 
Two-week 0.649 (0.025) 0.680 (0.032) 0.030 (-0.032, 0.093) 0.34 
Six-week 0.746 (0.016) 0.754 (0.023) 0.009 (-0.036, 0.054) 0.70 
Three-month 0.794 (0.017) 0.850 (0.022) 0.057 (0.014, 0.100) 0.01 
12-month 0.842 (0.019) 0.856 (0.023) 0.014 (-0.031, 0.059) 0.59 
Mean QALYs gained 
from baseline 0.798 (0.015) 0.831 (0.019) 0.033 (-0.005, 0.071) 0.09 
     
WOMAC Total Score    
Baseline  81.83 (0.90) 83.49 (1.17) 1.66 (-0.63, 3.96) 0.16 
Six-week 87.57 (1.34) 89.34 (1.56) 1.77 (-1.30, 4.84) 0.26 
Three-month 90.62 (0.99) 93.01 (1.20) 2.39 (0.04, 4.75) 0.05 
12-month 93.90 (0.68) 96.15 (0.98) 2.26 (0.33, 4.19) 0.02 
 *values are reported as means with the bootstrap standard error which is the standard deviation of the bootstrap 





3.4.2 Cost Outcomes  
We calculated total costs over the 12-month study period, and also costs by category (Table 3.4). 
The categories with the largest differences in cost between the MPP and MMV groups were the 
cost of the inpatient hospital ward stay (mean difference = -385.46, 95% CI: -940.75, 169.94; p = 
0.17), and paid caregiver assistance, which are higher in the MPP group. The difference in costs 
for other health care provider costs, including physical therapy and occupational therapy, was also 
large between the groups however these costs were higher in the standard group from the payer 
perspective, and higher in the midvastus group from a societal perspective (Table 3.4).  
 
For the base-case analysis (participants analyzed according to intention to treat) there was a 
statistically significant difference in total costs from the societal perspective favoring the 
midvastus group (mean difference= -6980.95, 95% CI: -13988.45, 26.56; p = 0.05) (Table 3.5). 
Participants in the midvastus group also incurred fewer costs from the payer perspective 
although not statistically significant (mean difference = -463.94, 95% CI: -1110.32, 182.52; p = 
0.16). When analyzed as treated, the difference in cost increases from both a payer and societal 
perspective with greater costs incurred by the MPP group. However, the difference from the 
payer perspective still does not reach statistical significance (mean difference = -529.20, 95% CI: 











Table 3.4. Cumulative costs by categories for patients in the MPP and MMV groups (base case). 
*values are reported as means with the bootstrap standard error which is the standard deviation of the bootstrap 
distribution – (Hesterberg, 2011) 
 







Hospital Costs  
    
Average TKA Procedure 5878.36  5878.36  -  - 
PACU  316.25 (27.91) 322.10 (61.47) 5.85 (-114.62, 
126.33) 
0.92 
Ward  1493.68 (276.88) 1108.27 (283.34) -385.46 (-940.75, 
169.94) 
0.17 
Total Hospital Costs  7640.66 (292.14) 7245.16 (306.78) (-996.77, 205.78) 0.20      
Health Professionals  
    
Family Physician Visits  52.82 (19.57) 44.60 (26.01)  -8.22 (-59.18, 
42.76) 
0.75 
Surgeon and Specialists 108.13 (17.74) 111.03 (19.94) 2.90 (-36.18, 
41.98) 
0.88 
Other Health Care 
Professional - HCP 
301.05 (19.91) 263.16 (26.58) -37.90 (-89.99, 
14.19) 
0.15 
Other Health Care 
Professional - SOC 
544.15 (70.92) 742.18 (143.82) 198.03 (-83.87, 
479.92) 
0.17 
     
Medication - HCP 42.94 (22.25) 56.58 (28.08) 13.64 (-41.39, 
68.67) 
0.63 
Medication - SOC 78.37 (18.54) 109.02 (41.01) 30.6463 (-49.73, 
111.02) 
0.46 
Tests and X-Rays  97.51 (7.75) 105.68 (11.62) 8.17 (-14.61, 
30.95) 
0.48 
Emergency Visits and 
Hospitalizations  









     
Indirect Costs  
    
Paid Caregiver 
Assistance 





















Table 3.5. Total costs with sensitivity analyses over the 12-month study period (2021 $CAD). 
*values are reported as means with the bootstrap standard error which is the standard deviation of the bootstrap 




From the payer perspective, there were three outliers with residuals greater than two standard 
deviations in the MPP group; two patients who stayed greater than 140 in the hospital 
postoperative, and one patient who had extreme pain and reported visits to the emergency room 
at two-weeks and three-months. When these patients were removed from the analysis, there is no 
apparent difference in cost between groups.  
From the societal perspective there was one patient in the MPP group that reported time off work 
from baseline to 12-months postoperative and the cost of hiring full time assistance. When 




 MPP TKA  MMV TKA  Mean Difference  P value 
 Mean (SD)  Mean (SD)  (95% CI)   
Payer Perspective     
Base Case  8330.76 (307.08) 7866.82 (329.83) -463.94 (-1110.32, 182.52) 0.16 
As Treated  8334.27 (275.96) 7805.06 (299.82) -529.20 (-1116.84, 58.43) 0.08 
Outliers 
Removed 7905.95 (144.96) 7866.83 (186.08)  -39.12584 (-403.83, 325.57) 0.83 
     
Societal Perspective     
Base Case  22078.13 (3446.42) 15097.19 (3575.32) -6980.95 (-13988.45, 26.56) 0.05 
As Treated  21877.39 (3085.75) 14440.36 (3263.55) -7437.03 (-13833.47, -1040.59) 0.02 
Outliers 





The results of the cost-effectiveness analysis are reported in Table 3.6. From the base case cost-
effectiveness analysis, the incremental cost from the societal perspective was -6980.95 and the 
incremental effect was 2.36, which indicates the midvastus approach dominates the standard 
medial parapatellar approach (less costs on average, and more effective on average). When 
patients were analyzed as treated from a societal perspective, the dominance was stronger. The 
midvastus approach remained dominated across all sensitivity analysis, although results were not 
statistically significant.  
Table 3.6. Incremental Cost-Effectiveness of the midvastus versus medial parapatellar approach 
for TKA. 
 Incremental Cost  Incremental Effect  ICER  
 (95% CI) (95% CI)  
QALYs    
Healthcare Payer Perspective    
Base Case  -463.94 (-1110.32, 182.52) 0.033 (-0.005, 0.071) Dominated  
As Treated  -529.20 (-1116.84, 58.43) 0.044 (0.008, 0.080) Dominated  
Outliers Removed  -39.12584 (-403.83, 325.57) 0.028 (-0.009, 0.065) Dominated  
    
Societal Perspective    
Base Case  -6980.95 (-13988.45, 26.56) 0.033 (-0.005, 0.071) Dominated  
As Treated  -7437.03 (-13833.47, -1040.59) 0.044 (0.008, 0.080) Dominated  
Outliers Removed  -4018.93 (-8531.77, 493.91) 0.031 (-0.007, 0.068) Dominated  
 
   
WOMAC    
Healthcare Payer Perspective    
Base Case  -463.94 (-1110.32, 182.52) 2.257 (0.328, 4.186) Dominated  
As Treated  -529.20 (-1116.84, 58.43) 1.908 (0.021, 3.795) Dominated  
Outliers Removed  -39.12584 (-403.83, 325.57) 1.877 (-0.109, 3.863) Dominated  
    
Societal Perspective    
Base Case  -6980.95 (-13988.45, 26.56) 2.257 (0.328, 4.186) Dominated  
As Treated  -7437.03 (-13833.47, -1040.59) 1.908 (0.021, 3.795) Dominated  




3.4.3.1 Net Benefit Regression 
From both the healthcare payer and societal perspectives, the incremental net benefit was greater 
than zero for all WTP values suggesting that the midvastus approach is cost-effective compared 
to the standard approach (Table 3.7).  
Table 3.7. Base-case net benefit regression results. 
 Healthcare Payer Societal 
WTP  INB (SD)  95% CI  P INB (SD)  95% CI  P 
QALYs      
0  583.80 (421.92) -243, 1410 0.17 4739.26 (3414.79) -1953, 11432 0.17 
1000 607.68 (429.15) -233, 1448 0.16 4763.15 (3416.21) -1932, 11458 0.16 
2000 631.56 (437.12) -225, 1488 0.15 4787.03 (3417.73) -1911, 11485 0.16 
3000 655.44 (445.79) -218, 1529 0.14 4810.91 (3419.37) -1890, 11512 0.16 
4000 679.32 (455.13) -212, 1571 0.14 4834.79 (3421.12) -1870, 11540 0.16 
5000 703.21 (465.09) -208, 1614 0.13 4858.67 (3422.97) -1850, 11567 0.16 
10000 822.61 (522.92) -202, 1847 0.12 4978.07 (3433.88) -1752, 11708 0.15 
20000 1061.42 (666.54) -244, 2367 0.11 5216.88 (3463.76) -1571, 12005 0.13 
30000 1300.22 (830.97) -328, 2928 0.12 5455.69 (3504.17) -1412, 12323 0.12 
40000 1539.03 (1006.06) -432, 3510 0.13 5694.50 (3554.74) -1272, 12661 0.11 
50000 1777.84 (1187.10) -548, 4104 0.13 5933.31 (3615.04) -1152, 13018 0.10 
       
 Healthcare Payer Societal 
WTP  INB (SD)  95% CI  P INB (SD)  95% CI  P 
WOMAC      
0  583.80 (421.92) -243, 1410 0.17 4739.26 (3414.79) -1953, 11432 0.17 
1000  2453.84 (1251.23) 1, 4906 0.05 6609.30 (3787.68) -814, 14033 0.08 
2000  4323.88 (2248.15) -82, 8730 0.05 8479.34 (4374.17) -93, 17052 0.05 
3000 6193.92 (3262.49) -200, 12588 0.06 10349.38 (5101.09) 351, 20347 0.04 
4000 8063.95 (4281.88) -328, 16456 0.06 12219.42 (5916.93) 622, 23816 0.04 
5000 9933.99 (5303.42) -460, 20328 0.06 14089.46 (6789.70) 781, 27397 0.04 
10000 19284.19 (10421.17) -1140, 39709 0.06 23439.65 (11535.4) 830.69, 46048 0.04 
20000 37984.59 (20667.08) -2522, 78491 0.07 42140.06 (21554.0) -105, 84385 0.05 
30000 56684.96 (30915.38) -3908, 117270 0.07 60840.4 (31720.49) -1330, 123011 0.06 
40000 75385.35 (41164.28) -5295, 156065 0.07 79540.8 (41927.42) -2635, 161717 0.06 
50000 94085.74 (51413.43) -6682, 194854 0.07 98241.26 (52151.06) -3972, 200455 0.06 
 *values are reported as means with the bootstrap standard error which is the standard deviation of the bootstrap distribution 





3.4.3.2 Cost Effectiveness Acceptability Curves  
The probability of the midvastus approach for TKA being a cost-effective strategy at different 
willingness to pay thresholds is presented in Figure 3.2. At a willingness to pay of $0, there is a 
greater than 90% chance that the midvastus approach is cost-effective when considering 
improvements in QALYs or WOMAC total scores. When considering willingness to pay per 
QALY, from a payer perspective the probability the midvastus approach is cost-effective is 
93.5% at a WTP value of $5000, while the probability is 92.0% at the same WTP value from the 
societal perspective.  
 
From the healthcare payer perspective if the willingness to pay value is $1000 per WOMAC 
outcome, the probability of cost-effectiveness is 97.5%, however as WTP goes up, the 
probability the approach is cost effective slightly decreases. At a WTP value of $2000/WOMAC 
the probability is 97.3%, at $5000/WOMAC it is 96.9%, and at $30000/WOMAC it is 96.5%. 
From a societal perspective, the probability the midvastus approach is cost-effective is 98.1% at 
a willingness to pay of $5000 per one point improvement in WOMAC total score and decreases 











Figure 3.2: Base-case cost-effectiveness acceptability curve (CEACs) displaying the probability 
that MMV TKA is cost-effective compared to MPP TKA from the healthcare payer and societal 
perspectives, over a range of willingness to pay values A) for an additional QALY gained and B) 
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3.5 Sensitivity Analysis  
In each of the sensitivity considerations, the INB was positive for all WTP values further 
suggesting the midvastus approach may be cost-effective compared to the standard medial 
parapatellar approach for TKA (Table 3.8). When analyzing patients as treated, at a willingness 
to pay value of $0, the probability the midvastus approach is cost-effective is 95.5% and 92.8% 
from the health care payer and societal perspectives respectively (Figure 3.3) 
 
The probability the midvastus approach is cost-effective at a willingness to pay value of $0 
decreases when analyzed with outliers removed. Although the incremental net benefit is greater 
than zero, the confidence intervals 95% CIs around the estimate are wide, and the probability of 
cost-effectiveness considering any outcome is estimated at 57.4% and 83.5% from the health 
























Table 3.8. Sensitivity analysis net benefit regression results. 
 
 
*values are reported as means with the bootstrap standard error which is the standard deviation of 






Figure 3.3: Sensitivity analysis cost-effectiveness acceptability curves (CEAC) displaying the 
probability that MMV TKA is cost-effective compared to MPP TKA from the healthcare payer 
and societal perspectives with participants analyzed as treated, and with outliers removed, over 
a range of willingness to pay values A) for an additional QALY gained and B) for an additional 
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This study aimed to estimate the cost-effectiveness of a midvastus approach for TKA compared 
to the standard medial parapatellar surgical approach in patients with knee OA at 12-months 
postoperative. The results of our study suggest midvastus TKA may be cost-effective compared 
to medial parapatellar TKA from the payer perspective at WTP values between $1000 and 
$2000, and WTP values between $2000 and $20,000 from the societal perspective. 
To our knowledge, this is the first full economic evaluation of midvastus TKA incorporating 
both direct and indirect costs alongside a randomized controlled trial with a 12-month follow-up. 
Previous studies evaluating the costs associated with minimally invasive TKA have focused on 
hospital costs and direct procedure-related costs covered by Medicaid or private insurance. Coon 
et al. (2005) found MIS TKA procedure charges to be US $8600 (26%) less than standard TKA, 
while King et al. (2011) found the difference in procedure cost to be US $1047 (7.2%) for 
minimally invasive TKA compared to traditional TKA. Similarly, we found the average hospital 
cost of patients in the MMV TKA group to be less than the hospital costs of the MPP group 
(mean difference = -$395.49, 95% CI = -996.77, 205.78; p = 0.20), although the magnitude of 
the difference was smaller (5.2%) and not statistically significant. There was considerable 
uncertainty around our estimate, and calculation of hospital costs at the patient level is a noted 
limitation of this study.  
In this study, we found the difference in overall costs from the payer perspective was -463.94 
(95% CI: -1110.32, 182.52; p = 0.16) in favor of the midvastus group in the base case analysis. 




around our estimate did not provide the certainty to conclude whether MMV or MPP is cost-
saving from this perspective.  It is possible these results did not reach statistical significance due 
to the small sample size.  
When we analyzed patients who crossed over in the group that they were treated, the differences 
in average costs from the health care payer and societal perspectives increase in favor of the 
midvastus group, with the 95% confidence intervals around our estimates suggesting significance 
although they remained similarly wide compared to the base case. Removing outliers from the 
analysis decreased the uncertainty around the cost estimates as the range of the 95% confidence 
intervals decreased from $1292.84 to $729.4, and $14015.01 to $9025.68 for the payer and 
societal perspective estimates, respectively. There were three outliers from the payer perspective 
and one outlier from the societal perspective, all in the medial parapatellar group. With these 
outliers removed, the difference in cost from the payer perspective greatly decreases, although 
due to the small sample size, and the related complications experienced by the outliers, this may 
be misleading.  
Across all sensitivity analyses, the costs from the societal perspective remained substantially 
greater in the medial parapatellar group. The difference in societal costs, which includes indirect 
costs such as time off paid employment, volunteering, caregiving, and out-of-pocket expenses 
for the patient or private insurance, was $6980.95 (95% CI: -13988.45, 26.56; p = 0.05) in the 
base case analysis. The cost difference seen is largely due to less time off paid employment and 
volunteer activities experienced by the midvastus group. The cost incurred for paid caregivers 
was also substantially lower in the midvastus group (mean difference: -539.59; 95% CI: -




approach enabled patients to return to work and activities of daily living sooner than MPP TKA 
patients, which is similar to what has been expected in the literature on less invasive surgical 
techniques (Berger et al., 2004; Bozic & Beringer, 2007). It is also possible that increased 
assistance and time off were required by the MPP TKA group as they experienced more knee 
pain following surgery (Zomar, 2020).  
The results of our net benefit regression analysis (Table 3.7) and CEAC (Figure 3.2) further 
support this conclusion, as they suggest there is over a 90% chance the midvastus approach is 
cost-effective at a willingness-to-pay value of 0. When considering a one-point improvement in 
WOMAC total score, the probability the midvastus approach is cost-effective is over 97.5% at a 
WTP value between $1000 and $2000 from the payer perspective and between $2000 and 
$20,000 from the societal perspective. At willingness to pay values greater than this, however, 
the probability goes down due to the uncertainty surrounding the difference in outcome 
measures. The probability that either intervention is cost-effective from any explored WTP value 
considering QALYs gained as the primary outcome does not reach greater than 95% in the base 
case. This is explained by the insignificant difference in QALYs gained between the two 
treatment groups (mean difference: 0.033; 95% CI: -0.005, 0.071; p = 0.09).  
Interestingly, the average cost incurred for other healthcare provider visits, such as physical 
therapy and occupational therapy visits, was greater in the midvastus group from the societal 
perspective. Based on the suggested quicker rehabilitation with less invasive surgical 





Similarly, a reduction in the use of pain-relief medications has previously been reported in 
studies comparing minimally invasive joint arthroplasty to standard arthroplasty (Aslam et al., 
2017; Laskin, 2005); however, few have investigated the long-term medication requirements or 
the costs associated. Our results indicate that over a 12-month time frame, the average cost of 
medications incurred by the MMV TKA group was higher than the MPP TKA group, although 
the difference was not significant. However, in our study, medications given prior to hospital 
discharge were not costed at the patient level. Medication use information was collected from 
patients following discharge, and the average cost of medications given to TKA patients in the 
hospital was used, which likely influenced results.  
The average time in the PACU and the inpatient ward was not significantly different between 
groups. This is similar to findings on the length of stay in most meta-analyses comparing the 
medial parapatellar and midvastus surgical approaches. Liu et al. (2014) and Xu et al. (2014) 
included the results of five randomized controlled trials comparing the two approaches and found 
no significant difference in hospital stay (p = 0.79).  
Unlike many studies, however, we did not find a statistically significant difference in operative 
and tourniquet times between the groups. Meta-analyses by Alcelik et al. (2012), Xu et al. 
(2014), and Liu et al. (2014) have all found significant differences (p<0.05) in the operative 
times between the two approaches, although there was significant heterogeneity among the 
studies included in all three analyses. These findings may be due to the inclusion of learning 
curve patients in included clinical studies. Studies investigating the learning curve associated 
with less invasive surgical approaches have found that operative times are substantially longer in 




eventually, no differences in surgical time are found after surgeons received adequate training 
(Migliorini et al., 2020). A meta-analysis by Onggo et al. (2020) also found significantly 
increased operative times for the MMV approach, although they noted this might be due to a 
variety of administrative factors, skin closure technique, and surgeon factors within the operating 
room, rather than the direct result of the technical demands of the MMV surgical approach.  
In both groups, there were improvements in WOMAC total scores relative to baseline at all 
follow-ups. Although the mean difference in total WOMAC score between groups at 12-months 
was statistically significant, it was not clinically significant. Clement et al. (2018) suggest a 
minimally clinically important difference (MCID) value of 10 for WOMAC total score after 
TKA. If considering a clinically important improvement of 10 points in WOMAC total score the 
midvastus approach is likely cost-effective at WTP values of $10000 from the payer perspective 
and between $30000 and $100000 from the societal perspective. 
 Compared to the literature, this study found that patients receiving MMV TKA had similar 
short-term outcomes but gains in WOMAC total and quality-of-life compared to MPP TKA 
patients farther out from surgery. In a study by Karpman & Smith (2009), 59 patients were 
randomized to receive MPP TKA, MMV TKA, or minimally invasive quadriceps sparing TKA 
and followed for two years. Although they found no difference in WOMAC scores in the MMV 
TKA group, compared to the MPP TKA group, they found the minimally invasive quadriceps 
sparing group demonstrated greater improvements in WOMAC pain and function scores up to 
three-months postoperative. Nestor et al. (2010) also found no difference in WOMAC or 12-Item 




postoperative, although their study was conducted with 27 patients undergoing bilateral TKA 
with the MMV versus MPP approaches.  
Lin et al. (2020) recently compared the two approaches using the Forgotten Joint Score (FJS). 
The FJS is another patient-reported outcome measure (PROM) tool developed for THA and 
TKA patients to assess awareness of the artificial joint, which can reflect patient satisfaction 
(Behrend et al, 2012; Thienpont et al., 2014). They found significant differences between the 
groups in favor of the midvastus approach at all follow-ups during the three-year study period. 
Although the tools are not perfectly comparable, this further supports the notion that patients' 
priorities after TKA may not be reflected well in conventional outcomes (Lin et al., 2020).  
Few other studies have reported on the long-term differences in PROMs, such as tools evaluating 
health-related quality-of-life between the surgical approaches. Most meta-analyses have focused 
on comparing the approaches using outcomes such as the visual analog scale, Knee Society 
Score, knee range of motion, time to straight leg raise, operative time, lateral retinacular release 
time, blood loss, hospital stay, and postoperative complications (Alcelik et al., 2012; Liu et al., 
2014; Xu et al., 2019).  
We have previously reported on the trajectory of pain, function using the timed up and go (TUG) 
test, motor power, and spatiotemporal gait outcomes experienced by our study population 
(Zomar, 2020). In these functional outcome measures, our findings were more in line with the 
existing literature (Alcelik et al., 2012; Liu et al., 2014; Xu et al., 2014; Aslam et al., 2019) as we 
found MMV TKA patients experience less pain early in the recovery period, although there was 





4.1 Strengths and Limitations  
There are several limitations to this study that should be acknowledged. Although this was a 
randomized trial and patient profiles were generally similar in both groups, there were a few 
differences in baseline characteristics (Table 3.1). Mean height (p = 0.044), weight (p = 0.001), 
and BMI (p = 0.014) were significantly higher in the MPP group when considering groups as 
randomized. When analyzing patients who crossed over in the group that they were treated, the 
difference in mean BMI reduces but remains significant (p = 0.049). In order to minimize the 
impact of these differences, we evaluated cost-effectiveness with adjustment for baseline 
variables (i.e., age, BMI, baseline WOMAC total score as covariates in the net benefit regression 
model).  
One major limitation to this study was the small sample size. As the main purpose of the trial 
was to inform the surgical protocol of a future randomized controlled trial comparing outpatient 
to inpatient TKA, we recruited patients over two years to gain a preliminary understanding of 
functional recovery. We did not find significant differences in the trajectory of recovery at 12-
weeks between MMV TKA and MPP TKA, suggesting either approach could be used to enable 
outpatient discharge. However, the results of this cost-effectiveness analysis indicate that over a 
one-year time period a difference in costs and outcomes may exist, although a larger sample size 
would provide greater certainty around estimates. The generalizability of this study may also be 
limited by the stringent inclusion criteria and the fact that all surgeries were performed at a single 
centre by arthroplasty surgeons who perform TKA at a high volume. Surgeon expertise may 




Another limitation of this study was that all hospital costs could not be calculated at the patient 
level. In the present study, the same implant was used for patients in both groups, therefore 
implant costs should be equal. Computer-assisted navigation was used for the midvastus group 
however given the expected cost of navigation (approximately $100 to $150 per patient) it is 
unlikely to have a large impact on the overall costs at one-year postoperative. Although not 
required to perform the midvastus approach, new surgical instrumentation and implants, as well 
as navigation systems and patient-specific instrumentation, have been developed for minimally 
invasive TKA (Migliorini et al., 2020). Further investigation on the cost-effectiveness and 
clinical advantages of these new tools is needed as the uncertainty around them has discouraged 
many surgeons from using less invasive techniques for TKA (Karachalios et al., 2008; Migliorini 
et al., 2020). 
Another possible limitation is the use of the self-reported resource utilization questionnaires 
administered at various intervals and missed check-ins due to COVID-19 restriction, making our 
data susceptible to recall bias. However, the demographics of those missed at six and nine 
months were not significantly different from the rest of the study population, and most were 
successfully contacted at the 12-month follow-up. Additionally, any limitations associated with 
the calculation of costs should apply equally to both study groups. 
A strength of this study was the use of a patient-blinded randomized design. To limit possible 
bias, both participants and research staff were kept blinded to group allocation until the 
participants reached the final study visit. Additionally, our effectiveness measures were patient-




groups which is a noted limitation, although when analyzed in the group they were treated, 
results did not significantly change.  
Another strength of this analysis was that we included indirect costs to patients and caregivers in 
the societal perspective. In a review on the economics of minimally invasive total joint 
arthroplasty, Bozic et al. (2007) highlights the importance of considering time to recovery and 
return to work. We are seeing the population of TKA patients getting younger, and the 
proportion of patients undergoing TKA who are active in the workforce is growing (Maradit 
Kremers et al., 2015). Additionally, as it is estimated that 80% of the overall costs related to OA 
are related to time off work and leisure activities for both patients and their caregivers (Gupta et 
al., 2005), understanding the costs related to productivity loss following TKA is important. 
Possibly the greatest strength of this study was that costs were collected and analyzed 
simultaneously with both generic and disease-specific patient-reported outcome measures. Full 
economic evaluations are necessary to understand the value for money and ensure patients are 
getting the best care given available resources. Additionally, using the net benefit regression 
framework allowed us to determine the likelihood of cost-effectiveness across a range of 






5 Conclusion  
At 1-year postoperative, midvastus TKA patients had higher WOMAC scores as well as lower 
average societal costs compared to medial parapatellar TKA patients. However, we cannot 
conclude with certainty that MMV TKA is cost-effective compared to MPP TKA. A long-term 
prospective study with an adequately powered sample size is necessary to determine the cost-
effectiveness of MMV TKA and MPP TKA in the osteoarthritis patient population. 
 
5.1 Future Directions 
This analysis was conducted using data from a pilot study where the purpose was to inform the 
surgical protocol of a future randomized controlled trial investigating the clinical and cost-
effectiveness of outpatient versus inpatient TKA. This trial will include more than 500 TKA and 
THA patients to estimate the safety and cost-effectiveness of outpatient arthroplasty over a 12-
month follow-up period.  
Establishing the safety and cost-effectiveness of outpatient TKA is essential as the prevalence of 
OA and the scarcity of healthcare resources continue to increase. Additionally, although reducing 
costs and freeing up hospital resources is a motivating factor for reducing the length of stay, 
existing literature also suggests that patients prefer to recover at home and have decreased length 
of rehabilitation (McDonald et al., 2014).  
During the COVID-19 pandemic, many joint replacement surgeries were cancelled to provide 
additional hospital capacity to care for COVID-19 patients (CIHI, 2021). Delayed surgeries can 
significantly impact the quality of life of patients waiting for joint replacement, who have lived 




possible solution to allow patients to receive timely treatment while reducing the need for 
inpatient hospital beds. Despite a lack of evidence supporting the safety and cost-effectiveness of 
outpatient arthroplasty, the number of outpatient TKAs performed doubled during the COVID-
19 pandemic, although they still only represented 1.3% of all knee replacements (CIHI, 2021). 
High-quality randomized control trials with full economic evaluations are needed to fully 
evaluate outpatient total joint arthroplasty and increase implementation (Zomar et al., 2020).  
The results of an earlier analysis on our study population found no significant differences in the 
trajectory of recovery between the MMV and MPP groups during the early postoperative period 
(Zomar, 2020). These findings were used to support the decision to use either surgical approach 
in outpatient TKA study patients. 
As the medial parapatellar and midvastus surgical approaches are the two most commonly used 
approaches for TKA, not restricting surgeons to one approach increases the generalizability of 
future results. However, given the differences in cost and effect seen between patients in the 
MPP and MMV groups at 12-months, the effect of surgical approach on long-term outcomes and 
cost should be considered in the analysis of future studies.  
This study highlights the importance of investigating patient-reported outcomes measures 
beyond the initial recovery period. Additionally, indirect costs should be considered along with 
resource use to get better estimates of the economic impact. Future studies with larger sample 
sizes can also provide more accurate estimates of patient-reported health outcomes and the cost-
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Appendix B: EQ-5D-5L descriptive system 
 
 
CAPS TKA Pilot  Database ID: __________ 
  Date: ________________ 
 
Version: 06-Sep -2017 
EQ-5D 
Under each heading, please tick the ONE box that best describes your health TODAY. 
MOBILITY 
I have no problems in walking about    ☐ 
I have slight problems in walking about   ☐ 
I have moderate problems in walking about   ☐ 
I have severe problems in walking about   ☐ 
I am unable to walk about     ☐ 
SELF-CARE 
I have no problems washing or dressing myself  ☐ 
I have slight problems washing or dressing myself  ☐ 
I have moderate problems washing or dressing myself ☐ 
I have severe problems washing or dressing myself  ☐ 
I am unable to wash or dress myself    ☐ 
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) 
I have no problems doing my usual activities  ☐ 
I have slight problems doing my usual activities  ☐ 
I have moderate problems doing my usual activities  ☐ 
I have severe problems doing my usual activities  ☐ 
I am unable to do my usual activities    ☐ 
PAIN / DISCOMFORT 
I have no pain or discomfort     ☐ 
I have slight pain or discomfort    ☐ 
I have moderate pain or discomfort    ☐ 
I have severe pain or discomfort    ☐ 
I have extreme pain or discomfort    ☐ 
ANXIETY / DEPRESSION 
I am not anxious or depressed    ☐ 
I am slightly anxious or depressed    ☐ 
I am moderately anxious or depressed   ☐ 
I am severely anxious or depressed    ☐ 






Appendix C: Western Ontario and McMaster Universities Osteoarthritis Index 
 
CAPS TKA Pilot  Database ID: __________ 




A. Think about the pain you felt in your hip/knee during the last 48 hours. 
Question: How much pain do you have? None Mild Moderate Severe Extreme 
1. Walking on a flat surface 0 1 2 3 4 
2. Going up or down stairs 0 1 2 3 4 
3. At night while in bed, pain disturbs your 
sleep 
0 1 2 3 4 
4. Sitting or lying 0 1 2 3 4 
5. Standing upright 0 1 2 3 4 
 
B. Think about the stiffness (not pain) you felt in your hip/knee during the last 48 hours. Stiffness is a 
sensation of decreased ease in moving your joint. 
 None Mild Moderate Severe Extreme 
6. How severe is your stiffness after first 
awakening in the morning? 
0 1 2 3 4 
7. How severe is your stiffness after sitting, 
lying, or resting later in the day? 
0 1 2 3 4 
 
C. Think about the difficulty you had in doing the following daily physical activities dues to your 
hip/knee during the last 48 hours. By this we mean your ability to move around and look after 
yourself. 
Question: What degree of difficulty do you 
have? 
None Mild Moderate Severe Extreme 
8. Descending stairs 0 1 2 3 4 
9. Ascending stairs 0 1 2 3 4 
10. Rising from sitting 0 1 2 3 4 
11. Standing 0 1 2 3 4 
12. Bending to the floor 0 1 2 3 4 
13. Walking on a flat surface 0 1 2 3 4 
14. Getting in and out of a car, or on or off a 
bus 
0 1 2 3 4 
15. Going shopping 0 1 2 3 4 
16. Putting on your socks or stockings 0 1 2 3 4 
17. Rising from bed 0 1 2 3 4 
18. Taking off your socks or stockings 0 1 2 3 4 
19. Lying in bed 0 1 2 3 4 
20. Getting in or out of the bath 0 1 2 3 4 
21. Sitting 0 1 2 3 4 
22. Getting on or off the toilet 0 1 2 3 4 
23. Performing heavy domestic duties 0 1 2 3 4 





Appendix D: Cost Questionnaires 
 
 




1) Did you call the hospital for any reason related to your knee today? 
 
No    Yes Æ    S ge n  ffice 
 
     Resident on call 
 
     Other (Please specify): 
 
1b) Reason for call? 
 
1c) Length of Call?   
 
2) Please record what medications you have taken today: 
 
Medication Name Dose Frequency (Dose/Day) 
   
   
   
   
   
 
3) Have you received assistance from a relative or a friend for health care, personal care, shopping, 
household activities or transportation? (Only list assistance needed because of your knee) 
 
No   Yes (Please Specify):  
 
Health Care Activity Number of hours of 
assistance 
Number of hours that person 
took off paid employment 
Taking Medications   
Exercises/Rehabilitation   
Dressing/Undressing   
Bathing/Showering   
Going to the bathroom   
Shopping   
Meal preparation   
Housework   
Finances   
Doctor appointments   
Driving   
Other:   
 
4) Did you incur any other expenses related to your knee, that we have not asked you about? Remember to 
include things like walking aids, gasoline, taxi, ambulance, parking, food, toiletries, etc) 
 
No    Yes (Please Specify):  
 





5) How bad is your pain today? Please mark your pain with a slash across the line ( / )  
No Pain  0  
 








CAPS TKA Pilot  Database ID: __________ 
  Date: ________________ 
Version: 06-Sep-2017 
Emergency Room Visits and Hospitalizations 
 
1. Since your last visit, have you visited an emergency room for any reason? 
 
  No – Skip to Question 2 
  Yes – How many times?                    If yes, which hospital did you go to and why? 
 
1 Reason:  
Hospital:  
2 Reason:  
Hospital:  
 
2. Since your last visit, have you been admitted to the hospital overnight for any reason 
(including overnight emergency room visits)? 
 
  No – Skip to Question 3 
  Yes – How many times?    Please complete the following: 
 
Admission Date:   Discharge Date:  
Days in ICU/CCU:  
Major surgery / 




Discharged to:  
 
Family Doctor Visits 
 
3. Since your last visit, have you seen your family doctor for any reason? 
 
I do not have a family physician - skip to Question 4 
I have not attended an appointment with my family physician since my last visit  
(skip to Question 4) 
Yes, I have attended an appointment with my family physician since my last visit. 
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Version: 06-Sep-2017 
Visit 1:  Reason:             
Check this box if the reason for visit was related to your knee replacement 
Visit 2:  Reason:             
Check this box if the reason for visit was related to your knee replacement 
 
Specialist Visits and Outpatient Clinics 
 
4. Since your last visit, have you visited a specialist for any reason (please include visits to 
the surgeon who performed your knee replacement)? If you are uncertain about the exact number 
of visits, please provide your best estimate. 
 
  No – Skip to Question 5 
  Yes – Complete the following: 
How many specialists? _______________ 
1: Specialist Visited: ________________________________________________________ 
Number of Visits: ________________________________________________________ 
Please specify reason for visit: ______________________________________________ 
2: Specialist Visited: ________________________________________________________ 
Number of Visits: ________________________________________________________ 
Please specify reason for visit: ______________________________________________ 
 
5. Since your last visit, have you visited any clinics for any reason (for example walk-in or 
pain management clinics)? If you are uncertain about the exact number of visits, please provide 
your best estimate. 
 
  No – Skip to Question 6 
 Yes – Complete the following: 
 
Type of clinic visited  Reason for Visit Number of 
visits 
Number of visits 
relating to your knee 
replacement? 
    
    









CAPS TKA Pilot  Database ID: __________ 
  Date: ________________ 
Version: 06-Sep-2017 
Other Health Care Professionals 
 
6. Since your last visit, have you seen any other health professionals (like a physiotherapist, 
occupational therapist, etc)? If you are uncertain about the exact number of visits, please 
provide your best estimate. 
 
  No – Skip to Question 7 
  Yes – Complete the following: 
Since your last visit, how many times have you visited a physiotherapist? ___________ 
Was this visit because 
of your knee 
replacement? 
Cost of this 
visit 
How was the visit paid for? 
Yes     No $ OHIP       Out of pocket    Private insurance 
Yes     No $ OHIP       Out of pocket    Private insurance 
Yes     No $ OHIP       Out of pocket    Private insurance 
Yes     No $ OHIP       Out of pocket    Private insurance 
 
Since your last visit, how many times have you visited an occupational therapist? _______ 
Was this visit because 
of your knee 
replacement? 
Cost of this 
visit 
How was the visit paid for? 
Yes     No $ OHIP       Out of pocket    Private insurance 
Yes     No $ OHIP       Out of pocket    Private insurance 
 
Since your last visit, how many other health professionals have you visited (for example a 









How was the visit paid for? 
   $ OHIP     Private insurance 
Out of pocket 
   $ OHIP     Private insurance 
Out of pocket 
   $ OHIP     Private insurance 
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Tests, Procedures, and Surgeries 
 
7. Since your last visit, have you had any tests, procedures, or surgeries for any reason (for 
example x-rays or blood tests)? 
 
  No – Skip to Question 8 
  Yes – Complete the following: 




Number of tests 
related to your 
knee 
replacement? 
Where did you receive this test or 
procedure? 
   Emergency room         Hospital, inpatient 
Hospital, outpatient    Rehab Centre 
Other, specify: 
   Emergency room         Hospital, inpatient 
Hospital, outpatient    Rehab Centre 
Other, specify: 
 
Employment Status and Time-Off Work from Paid Employment 
 
8. When you were enrolled in this study, were you actively employed? 
 
 No - skip to Question 10 
 Yes  
 
9. Which of the following best describes your employment status or main activity at the 
time of study enrollment? 
 
 Employed (full time) 




 Social Assistance 
 Retired 










What was your occupation? ____________________________________________ 
 
10. Has there been any change to your employment status since your last visit? 
 
 No - skip to Question 11 
 Yes – Please complete the following: 
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11. Since your last visit, how much time off paid employment did you take off as a result of 
your health? (includes hospitalization, doctor / emergency visits, treatment, and rehabilitation)  
    Days 
    Hours 
None 
 





 $20,000-$40,000  $80,000-$100,000 
 $40,000-$60,000  >$100,000 
  
Homemaking and Volunteer Activities 
 
13. Since your last visit, how much time off homemaking activities did you take off as a 
result of your health (including hospitalization, doctor / emergency visits, treatment, and 
rehabilitation)? 
    Days 
    Hours 
None 
 
14. Since your last visit, how much time off volunteer activities did you take off as a result 
of your health (including hospitalization, doctor / emergency visits, treatment, and 
rehabilitation)? 
    Days 
    Hours 
None 
 
15. This section is asking about your role as a primary caregiver.  
 
Definition: Primary caregiver is an individual who is responsible for providing care 
assistance, companionship, and/or supervision to another person. 
 
Since your last visit, 
 I have not been a primary caregiver - skip to Question 16 
 I have been a primary caregiver. My role has NOT changed 
If you had to take days off from primary caregiving, how many days did you take 
off because of your knee (including hospitalizations, doctor visits, treatment and 
rehabilitation)? 
       Days 
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 I was a primary caregiver and now I am NO LONGER a primary caregiver 
  
Date of change:  |___|___|___|___|/|___|___|___|/|___|___| 
   yyyy    /      mmm /   dd 
Reason for no longer being a primary caregiver:      
 
             
 
I was NOT a primary caregiver and now I AM a primary caregiver 
  
Date of change:  |___|___|___|___|/|___|___|___|/|___|___| 
   yyyy    /      mmm /   dd  
Reason for becoming a primary caregiver:       
 
             
How many days of primary caregiving did you provide? 
       Days 





16. Since your last visit, has there been a change to your living status? (for example, did you 
move in with a relative, move into a rehabilitation facility or move back home?) 
 
  No – Skip to Question 17 
  Yes – Complete the following: 
Is the change in living status related to your knee replacement?  
 Yes    No – skip to Question 17 
If yes, which option best describes the change in your living status: 
 Living in own home – no hired assistance    
Date Changed:        
 Living in own home – hired assistance required   
Date Changed:        
Please indicate the source of funding and total charge. 
    Publicly funded $     
    Insurance funded $     
    Private funded $     
   Living in relative s home – no hired assistance   
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 Living in relative s home – hired assistance required  
Date Changed:        
Please indicate the source of funding and total charge. 
    Publicly funded $     
    Insurance funded $     
    Private funded $     
   Supportive housing / personal care home    
Date Changed:        
   Type of assisted living: 
    Assisted living (group home, retirement home) 
    Residential care 
    Long-term care facility, convalescent care, nursing home 
Please indicate the source of funding and total charge. 
    Publicly funded $     
    Insurance funded $     
    Private funded $      
 
17. Did you incur any other expenses related to your knee replacement that we have not 
asked you about? (e.g. gasoline, walking aids, meals, accommodation, parking, etc) 
 
  No  
  Yes – please specify, with approximate cost: 
 
Expense:       $ cost:     
Expense:       $ cost:     
Expense:       $ cost:     
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Medications 
 
18. Since your last visit, have you taken any prescription or over-the-counter medications 
for your knee? 
 
  No – Skip to Question 19 
  Yes – Complete the following: 
Yes No 
  Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
Medication Dose (mcg, mg, 
g, other) 
Pills/dose Doses/day How many 
days? 
Aspirin     
Celebrex     
Indomethacin     
Ibuprofen (Advil)     
Diclofenac (Arthrotec)     
Mobicox (Meloxicam)     
Naproxen (Naprosyn)     
Other, specify:     
Yes No 
  Steroids (please list) 
Name of steroid Dose (mcg, mg, 
g, other) 
Pills/dose Doses/day How many 
days? 
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Yes No 
  Anti-Rheumatoid Drugs 
Medication Dose (mcg, mg, 
g, other) 
Pills/dose Doses/day How many 
days? 
Plaquenil (hydroxychloraquine)     
Aralen (chloroquine)     
Arava (Leflunomide)     
Rheumatrex (Methotrexate)     
Azulfidine (Sulfasalazine)     
Remicade (Infliximab)     
Enbrel (Etanercept)     
Humira (Adalimumab)     
Other     
Yes No 
  Pain Killers 
Medication Dose (mcg, mg, 
g, other) 
Pills/dose Doses/day How many 
days? 
Tylenol Regular Strength     
Tylenol Extra Strength     
Tylenol 2, 3     
Percocets     
Tramacet     
Hydromorphone (Dilaudid)     
Gabapentin     
Lyrica     
Oxycodone     
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19. Since your last visit, did you take any other medications? Examples would include 
antibiotics related to your knee replacement, or medications to prevent blood clots (i.e. Fragmin, 
Xeralto, Pradaxa). 
  
 No – Skip to Question 20 
 Yes – Please record the name of the medication or D.I.N. number (Drug Identification 
Number – found at the bottom of the prescription label on your medication bottle), 












Start / End date How did you pay for 
this medication? 
    Start:  OHIP      
Private insurance 
Out of pocket End:  
    Start:  OHIP      
Private insurance 
Out of pocket End:  
    Start:  OHIP      
Private insurance 
Out of pocket End:  
    Start:  OHIP      
Private insurance 
Out of pocket End:  
 
Assistance from Others 
 
20. Since your last visit, have you received assistance from a relative or a friend for health 
care, personal care, shopping, household activities, or transportation because of your 
health? 
  No  
  Yes – Complete the following: 




because of knee 
replacement? 
Number of hours off paid 
employment 
Taking Medications  Yes     No  
Exercises / Rehab  Yes     No  
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because of knee 
replacement? 
Number of hours off paid 
employment 
 Dressing/Undressing  Yes     No  
 Bathing/Showering  Yes     No  
 Going to the bathroom  Yes     No  
Grooming (hair, 
shaving) 
 Yes     No  
 




because of knee 
replacement? 
Number of hours off paid 
employment 
 Shopping (groceries)  Yes     No  
 Meal Preparation  Yes     No  
 Housework  Yes     No  
 Managing Finances  Yes     No  
 Other:     Yes     No  
 
 




because of knee 
replacement? 
Number of hours off paid 
employment 
 Doctor   Yes     No  
 Physiotherapist  Yes     No  
 Bank  Yes     No  
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